Mode
Text Size
Log in / Sign up
N/A N=40 Randomized Treatment

An RCT Comparing Xenograft and Allograft for Ridge Preservation

Tooth Loss

Enrolled (actual)
40
Serious AEs
0.0%
Results posted
Feb 2016
Primary outcome: Primary: Bone Ridge Buccal-Lingual and Apico-Coronal Measures at 6 Months — 4.95; 6.71; 5.29; 6.24 mm

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
allograft + x-link collagen membrane (Device); xenograft + non-x-link collagen (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
McGuire Institute
Primary completion
Dec 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Bone Ridge Buccal-Lingual and Apico-Coronal Measures at 6 Months
4.95; 6.71; 5.29; 6.24
SECONDARY
New Bone Plus Graft Content at 6-months
46.14; 49.21
SECONDARY
Wound Closure at 4-weeks
2.26; 0.79

Summary

To compare the effectiveness of demineralized freeze-dried bone allograft + cross-linked collagen membrane with xenograft + non-cross-linked collagen membrane for posterior extraction socket ridge preservation.

Eligibility Criteria

Inclusion Criteria

  • Subjects 18 to 70-yrs of age
  • Subject indicated for posterior tooth extraction (from 1st premolar to 1st molar) intended for implant placement, with adjacent teeth intact (for stent indexing)
  • Subjects with extraction site bony buccal dehiscences at least 1/3 the depth of socket and 1/3 the mesial-distal width of tooth socket
  • Subjects will have read, understood and signed an institutional review board (IRB) approved Informed Consent Form (ICF).
  • Subjects must be able and willing to follow study procedures and instructions.

Exclusion Criteria

  • Subjects with a history of any tobacco use within the last six months.
  • Subjects with healing disorders (i.e., diabetes mellitus, cancer, HIV, bone metabolic diseases) that could compromise wound healing and/ or preclude implant surgery; or who are currently receiving or have received within two months prior to study entry, systemic corticosteroids, immunosuppressive agents, radiation therapy, and/or chemotherapy which could compromise wound healing and preclude periodontal surgery.
  • Subjects taking intramuscular or intravenous bisphosphonates.
  • Subjects who have a known allergy or sensitivity to alginate, latex, collagen or acrylic.
  • Female subjects who are pregnant or lactating, or who intend to become pregnant during the study duration
  • Subjects participating in other clinical studies involving therapeutic intervention (either medical or dental).
  • Subjects, who in the opinion of the investigator, for any reason other than those listed above, will not be able to complete the study per protocol.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02330523). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search